Compare · NVS vs YMAB
NVS vs YMAB
Side-by-side comparison of Novartis AG (NVS) and Y-mAbs Therapeutics Inc. (YMAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and YMAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $306.26B.
- NVS has hit the wire 5 times in the past 4 weeks while YMAB has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 20 for YMAB).
- Company
- Novartis AG
- Y-mAbs Therapeutics Inc.
- Price
- $160.53+0.17%
- -
- Market cap
- $306.26B
- -
- 1M return
- +6.79%
- -
- 1Y return
- +22.07%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 20
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest YMAB
- SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.
- Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J
- Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)
- Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)